<DOC>
	<DOCNO>NCT02331602</DOCNO>
	<brief_summary>The purpose study evaluate antiinflammatory effect rivaroxaban compare dabigatran patient atrial fibrillation .</brief_summary>
	<brief_title>Anti-inflammatory Effects Rivaroxaban Versus Dabigatran</brief_title>
	<detailed_description>Previous study show administration rivaroxaban reduce expression proinflammatory mediator apolipoprotein E-deficient mouse . However , unknown whether anti-inflammatory marker decrease patient atrial fibrillation receive novel oral anticoagulant .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>nonvalvular atrial fibrillation CHADS2VASc score 1 contraindication rivaroxaban dabigatran stroke systemic embolism , acute coronary syndrome peripheral artery disease within 6 month enrollment acute heart failure severe chronic renal failure ( creatinine clearance &lt; 30mL/min . ) receive dual antiplatelet therapy patient body weight 50kg less uncontrolled hypertension active malignancy , collagen disease , infectious disease patient undergo surgery within 6 month enrollment patient plan undergoing catheter ablation atrial fibrillation patient allow participate trial judgement treat physician</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>anticoagulation</keyword>
	<keyword>inflammation</keyword>
</DOC>